The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma
Open accessAbstract
Background. Angiotensin-2 type-1 receptor antagonists not are only antihypertensive drugs but also can inhibit VEGF production. We hypothesised that adding telmisartan to sunitinib could potentiate the antiangiogenic effects.Material and Methods. 786-O cell lines were injected in nude mice. After tumor development, mice were divided into 4 groups: the first was the control group (DMSO), the second group was treated with sunitinib alone, the third group was treated with telmisartan alone, and the fourth group was treated with the combination. Drugs were orally administered every day for four weeks. Animals were sacrificed after treatment. Blood and tumor tissues were collected for analysis by immunohistochemistry, Western Blot, and ELISA methods.Results. All animals developed a ccRCC and ten in each group were treated. Using a kinetic model, tumors tended to grow slower in the combination group compared to others (P=0.06). Compared to sunitinib alone, the addition of telmisartan significantly increased tissue necrosis (P=0.038). Central microvascular density decreased (P=0.0038) as well as circulating VEGF (P=0.003). There was no significant variation in proliferation or apoptosis markers.Conclusion. The combination of sunitinib and telmisartan revealed an enhancement of the blockage of the VEGF pathway on renal tumor resulting in a decrease in neoangiogenesis and an increase in necrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
Sipahi, I., Debanne, S. M., Rowland, D. Y., Simon, D. I., & Fang, J. C. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70106-6 · Cited by 481
Angiotensin receptors: a new role in cancer?
Deshayes, F., & Nahmias, C. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.07.009 · Cited by 437
Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins
Chae, Y. K., Valsecchi, M. E., Kim, J., Bianchi, A. L., Khemasuwan, D., Desai, A., & Tester, W. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.616252 · Cited by 174
Hypertension as a predictive factor of Sunitinib activity
Rixe, O., Billemont, B., & Izzedine, H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm184 · Cited by 166
Wilop, S., von Hobe, S., Crysandt, M., Esser, A., Osieka, R., & Jost, E. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0587-3 · Cited by 163
Cited by
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
Mechanism of Zinc absorption in plants: uptake, transport, translocation and accumulation
Gupta, N., Ram, H., & Kumar, B. (2016) · Reviews in Environmental Science and Bio/Technology · doi:10.1007/s11157-016-9390-1 · Cited by 505
Electrospun nanofibers for wound healing
Liu, M., Duan, X.-P., Li, Y.-M., Yang, D.-P., & Long, Y.-Z. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.03.034 · Cited by 487
Adsorption of methyl orange: A review on adsorbent performance
Iwuozor, K. O., Ighalo, J. O., Emenike, E. C., Ogunfowora, L. A., & Igwegbe, C. A. (2021) · Current Research in Green and Sustainable Chemistry · doi:10.1016/j.crgsc.2021.100179 · Cited by 301
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
Metadata
- Authors
- Verhoest, G., Dolley-Hitze, T., Jouan, F., Belaud-Rotureau, M.-A., Oger, E., Lavenu, A., Bensalah, K., Arlot-Bonnemains, Y., Collet, N., Rioux-Leclercq, N., & Vigneau, C.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-9
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2123285648
- Cited by
- 260
- References
- 24
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1155/2014/901371
- The paper
- Verhoest, G., Dolley-Hitze, T., Jouan, F., Belaud-Rotureau, M.-A., Oger, E., Lavenu, A., Bensalah, K., Arlot-Bonnemains, Y., Collet, N., Rioux-Leclercq, N., & Vigneau, C. (2014). Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma. BioMed Research International. https://doi.org/10.1155/2014/901371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.